You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 positive

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Breast Cancer Trial in Taizhou (Pyrotinib)

Recruiting
  • Breast Cancer
  • Taizhou, Zhejiang, China
    Taizhou Hospital
May 26, 2023

HER2-Positive Cancer Trial in Wuhan

Active, not recruiting
  • HER2-Positive Cancer
    • Wuhan, Hubei, China
      TongjiHospital
    Sep 7, 2022

    Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Apr 22, 2023

    t Pathologic Complete Response Observed in HER2 Positive Breast

    Completed
    • HER2+ Breast Cancer
    • Rawalpindi, Punjab, Pakistan
      Rawalpindi Medical University
    Jun 26, 2023

    HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

    Not yet recruiting
    • HER2-PositiveRecurrent or Metastatic Breast Cancer
    • SHR-A1811 Injection
    • +2 more
    • (no location specified)
    Sep 21, 2023

    Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Combination use of SRT with T-DXd
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 14, 2023

    HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)

    Recruiting
    • HER2 Gene Mutation
    • Injection of IAH0968+Gemcitabine+Cisplatin
    • Gemcitabine+Cisplatin
    • Shanghai, China
      Fudan University Affiliated Zhongshan Hospital
    Aug 7, 2023

    HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)

    Recruiting
    • HER-2 Positive Breast Cancer
    • TCbHP VS ddEC-THP
    • Tianjin, Tianjin, China
      Breast Oncology, Tianjin Medical University Cancer Institute and
    May 15, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)

    Completed
    • Advanced Gastric Carcinoma
    • Dhaka, Bangladesh
      Bangabandhu Sheikh Mujib Medical University
    Aug 15, 2023

    HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

    Completed
    • HER2-positive Breast Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital (First Affiliated Hospital of
    Oct 25, 2023

    HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Trastuzumab deruxtecan
    • Amsterdam, Netherlands
      Antoni van Leeuwenhoek
    Aug 7, 2023

    Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)

    Recruiting
    • Triple Negative Breast Cancer
    • HER2-positive Breast Cancer
    • proton plus carbon ion radiotherapy
    • Shanghai, China
      Shanghai Proton and Heavy Ion center
    Jan 11, 2023

    T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

    Recruiting
    • Breast Cancer
    • Beijing, Beijing, China
    • +1 more
    Nov 13, 2023

    HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

    Not yet recruiting
    • HER2-positive Advanced Gastric Cancer
    • trastuzumab, bevacizumab with paclitaxel (triple combination)
    • (no location specified)
    Dec 6, 2022

    Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

    Recruiting
    • Breast Cancer With Brain Metastases
    • Wuhan, Hubei, China
      Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
    Nov 22, 2023

    Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)

    Not yet recruiting
    • Breast Cancer
    • Disitamb Vedotin ,pyrotinib
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Aug 18, 2023

    HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

    Not yet recruiting
    • HER2-positive Recurrent/Metastatic Breast Cancer
    • Inetetamab, pyrotinib, chemotherapy
    • (no location specified)
    Nov 16, 2022

    Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

    Recruiting
    • Breast Cancer
    • Whole breast irradiation +/- tumor bed boost
    • Seoul, Korea, Republic of
      Samsung Medical Center
    May 30, 2023

    Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)

    Active, not recruiting
    • Advanced/ Metastatic Her-2 Positive Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 15, 2022

    Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Jul 12, 2023

    Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)

    Not yet recruiting
    • Breast Cancer
    • Disitamab Vedotin plus pyrotinib or naratinib
    • Xi'an, Shaanxi, China
      Xi'an International Medical Center Hospital
    Aug 27, 2023

    Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

    Not yet recruiting
    • Non-muscle Invasive Bladder Cancer
    • Chengdu, Sichuan, China
      West China Hospital
    Aug 10, 2023

    Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

    Recruiting
    • Breast Neoplasm Female
    • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
    • Beijing, Beijing, China
    • +1 more
    Jul 31, 2023